HopeStage
Back to all studies
CompletedNCT05624268

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Medication studyAges 18+United StatesDepression
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
Tuscon, United States · Culver City, United States and 31 more locationsSee all locations and recruitment
Activities
Medication and placebo comparator listed across study groups
Compensation
Payment and expense reimbursement have not been verified.
Study clarity

Study information

Study start dateStarted: January 24, 2023
Recruitment status
Completed
Enrollment listed in the registry
258
Sponsor
COMPASS Pathways
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT05624268
Official title
Show the full official title

A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Tuscon · Culver City · Garden Grove

30 more locations
  • La Jolla
  • Los Angeles
  • Orange
  • San Diego
  • San Jose
  • Stanford
  • Thousand Oaks
  • Norwich
  • Orlando
  • Tampa
  • Atlanta
  • Chicago
  • Baltimore
  • Gaithersburg
  • Pikesville
  • North Worcester
  • Minneapolis
  • Columbia
  • Saint Charles
  • St Louis
  • Lincoln
  • Toms River
  • New York
  • Beachwood
  • North Canton
  • Oklahoma City
  • Moosic
  • Houston
  • Draper
  • Everett
FAQ

Questions about this study

Who is behind this study?

The study sponsor is COMPASS Pathways.

Did this study involve medication?

Yes. The study involved medication, including Psilocybin.

Who was this study for?

This study was for people with depression. Listed age limits: from 18 years. Other eligibility criteria applied.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me